These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23380546)

  • 1. Coinhibitory molecules in cancer biology and therapy.
    Mocellin S; Benna C; Pilati P
    Cytokine Growth Factor Rev; 2013 Apr; 24(2):147-61. PubMed ID: 23380546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTLA-4 blockade and the renaissance of cancer immunotherapy.
    Mocellin S; Nitti D
    Biochim Biophys Acta; 2013 Dec; 1836(2):187-96. PubMed ID: 23748107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B7 family checkpoint regulators in immune regulation and disease.
    Ceeraz S; Nowak EC; Noelle RJ
    Trends Immunol; 2013 Nov; 34(11):556-63. PubMed ID: 23954143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint blockade therapy: the 2014 Tang Prize in Biopharmaceutical Science.
    Chen YS; Shen CR
    Biomed J; 2015; 38(1):5-8. PubMed ID: 25673064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer.
    Stamm H; Wellbrock J; Fiedler W
    Mamm Genome; 2018 Dec; 29(11-12):694-702. PubMed ID: 30132062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
    Simeone E; Ascierto PA
    J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint blocking antibodies in cancer immunotherapy.
    Kyi C; Postow MA
    FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy and toll-like receptor agonists.
    Marabelle A; Filatenkov A; Sagiv-Barfi I; Kohrt H
    Semin Radiat Oncol; 2015 Jan; 25(1):34-9. PubMed ID: 25481264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
    Weber J
    Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
    Bakacs T; Mehrishi JN; Moss RW
    Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects for TIM3-Targeted Antitumor Immunotherapy.
    Ngiow SF; Teng MW; Smyth MJ
    Cancer Res; 2011 Nov; 71(21):6567-71. PubMed ID: 22009533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations.
    Baksh K; Weber J
    Semin Oncol; 2015 Jun; 42(3):363-77. PubMed ID: 25965355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immune-checkpoints: the new anti-cancer immunotherapies].
    Ileana E; Champiat S; Soria JC
    Bull Cancer; 2013 Jun; 100(6):601-10. PubMed ID: 23735730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity.
    Pasero C; Olive D
    Immunol Lett; 2013 Mar; 151(1-2):71-5. PubMed ID: 23439006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
    Shin DS; Ribas A
    Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors.
    Haanen JB; Robert C
    Prog Tumor Res; 2015; 42():55-66. PubMed ID: 26382943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective cancer therapy through immunomodulation.
    Waldmann TA
    Annu Rev Med; 2006; 57():65-81. PubMed ID: 16409137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lymphocyte receptors that regulate the immune-response--the key to the management of antitumor immunity].
    Kadagidze ZG; Slavina EG; Chertkova AI
    Vopr Onkol; 2015; 61(4):523-9. PubMed ID: 26571819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.